{
    "nctId": "NCT04362462",
    "briefTitle": "Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer",
    "officialTitle": "Genomic/Molecular Profiling of Residual Disease After Neoadjuvant Chemotherapy in Hispanic/ Latino Women With Triple-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \\> 18 or \\<86 years of age, for Hispanic/Latino women we will use the National Advisory Committee on Racial, Ethnic and Other populations NAC definition which is (the ethnonyms \"Hispanic\" and \"Latino\" to refer collectively to the inhabitants of the United States of America who are of Latin American or Spanish origin-that is, Latino or Hispanic Americans).\n2. Pre- and Post - menopausal women with histologically confirmed hormonal receptor negative (ER and/or PR \\<1%), Her2-neu - negative (by IHC or/and FISH) invasive breast cancer stages I - III or with metastatic triple-negative breast cancer (if develop metastatic disease during the chemotherapy or within 24 months after completion of all appropriate treatments).\n3. Patient must be eligible for neo-adjuvant chemotherapy, and surgical lumpectomy or mastectomy.\n4. All patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with Institutional and Federal guidelines.\n\nExclusion Criteria:\n\n1. Women \\< 18 or \\>86 years of age\n2. ER/PR- positive, Her-2 neu - positive breast cancer.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}